The global amniotic membrane market size was valued at USD 4.28 billion in 2025 and is projected to grow from USD 4.84 billion in 2026 to USD 13.06 billion by 2034, registering a CAGR of 13.2% during the forecast period from 2026 to 2034. North America dominated the amniotic membrane market with a market share of 39.2% in 2025.
The amniotic membrane is the innermost layer of the fetal membranes surrounding the developing fetus during pregnancy. It consists of a thin, transparent tissue containing extracellular matrix components, growth factors, and biologically active substances that support tissue healing. Amniotic membrane is used in medical applications such as wound care, ophthalmology, burn treatment, and tissue repair because of its protective, anti-inflammatory, and regenerative properties.
Download a Free Sample To learn more about this report,
Development of Amniotic Membrane Products for Orthopedic Applications
The Amniotic Membrane Market analysis shows that interest in biologic approaches for musculoskeletal conditions is encouraging the development of amniotic membrane products for tendon, ligament, cartilage, bone, and osteoarthritis applications. This transition is expanding amniotic-derived materials beyond established wound-care and ophthalmic uses toward orthopedic regenerative applications, although current human evidence remains limited and clinical outcomes are not yet conclusive. For example, a 2024 orthopedic review examined amniotic-derived products across conditions including osteoarthritis, Achilles tendinopathy, plantar fasciitis, cartilage defects, tendon repair, and fracture healing, while emphasizing the need for further studies on long-term outcomes.
Adoption of Processed Amniotic Membrane Allografts for Chronic Wounds
The need for advanced treatment options for diabetic, venous, and other chronic wounds is supporting the use of processed amniotic membrane allografts as biological wound coverings. This transition is providing clinicians with additional approaches for difficult-to-heal wounds, with a 2026 systematic review and meta-analysis covering 14 randomized controlled trials and 1,056 participants reporting improved complete-healing outcomes with human amniotic membrane therapy compared with conventional management. For example, earlier clinical literature has reported randomized controlled trials involving more than 200 patients collectively for dehydrated human amnion/chorion membrane products, with improved healing reported across the studies reviewed.
Donor Tissue Availability and Plastic Surgery Applications Drive Market
The availability of placental tissue from eligible donors provides a direct raw-material base for amniotic membrane products. Organized recovery programs allow tissue establishments to collect, screen, process, and store amniotic membranes under controlled procedures. For example, the U.S. FDA documents placenta recovery, donor eligibility assessment, processing, and final release as part of the manufacturing pathway for a human-sourced decellularized amniotic membrane product. This organized supply chain improves access to suitable donor tissue and supports consistent product availability for healthcare applications.
The use of amniotic membrane in plastic and reconstructive procedures creates requirements for biologic materials that support tissue repair and wound coverage. Plastic and reconstructive surgeons can use amniotic membrane in applications involving soft-tissue repair, burns, and biological wound coverage. For example, amniotic membrane has been used as a biological material in reconstructive procedures to support tissue healing and coverage of damaged areas. This broader surgical application supports utilization of amniotic membrane products and provides suppliers with additional clinical-use opportunities.
Donor Tissue Availability and Clinical Evidence Restrain Market Expansion
Limited availability of donated amniotic tissue depends on donor volumes, screening capacity, and tissue-bank infrastructure. Restricted supply can make consistent sourcing difficult and increase procurement and processing costs for manufacturers. These supply constraints can limit product availability and slow the expansion of the amniotic membrane market.
Limited clinical evidence for certain applications can create uncertainty about the safety, effectiveness, and long-term benefits of amniotic membrane products. This uncertainty can make healthcare providers more cautious about adopting these products beyond established clinical uses. Lower clinical confidence can delay adoption and restrict market growth across emerging applications.
Ophthalmic and Dental Applications of Amniotic Membrane Offers Growth Opportunities
Tissue-product manufacturers and ophthalmology providers can develop amniotic membrane solutions for ocular surface reconstruction and corneal healing. A 2024 meta-analysis covering 9 studies and 408 participants found favorable and consistent outcomes for fresh and preserved amniotic membranes in ocular surface reconstruction. These applications create revenue through specialized ophthalmic products and hospital supply agreements, supporting market growth.
Dental clinics, oral surgeons, and tissue-product companies can use amniotic membrane products for periodontal and oral tissue regeneration. A systematic review covered 21 clinical studies involving 375 patients across applications including gingival recession, dental implants, and oral tissue reconstruction. These applications create revenue through specialized dental products and clinical supply contracts, supporting market growth.
Processing Complexity and Hospital Procurement Hinders Growth
Amniotic membranes require controlled collection, processing, sterilization, preservation, and storage to maintain product integrity, with FDA guidance specifically covering microbial testing, sterilization, preservation, and processing controls for human tissue products. These requirements increase operational complexity and quality-control demands, making it more difficult for manufacturers to scale production efficiently. An FDA warning letter to an amniotic membrane manufacturer also documented deficiencies in equipment maintenance and current good tissue-practice procedures, illustrating the operational challenges involved in maintaining compliant processing systems.
Hospitals and healthcare systems often require product evaluation, technical specifications, budget planning, supplier assessment, and formal procurement procedures before adopting specialized biological wound-care products. WHO notes that medical-device procurement can involve technology assessment, device evaluation, needs assessment, procurement, installation, commissioning, and monitoring, while formal tenders may require competitive bidding. These multi-stage processes can lengthen sales cycles, delay product adoption, and make revenue growth less predictable for amniotic membrane manufacturers.
The cryopreserved segment accounted for a share of 62.5% in 2025, owing to its widespread use in wound care, ophthalmology, and surgical applications, along with its ability to preserve the biological properties of amniotic tissue. the established clinical adoption of cryopreserved amniotic membranes and their availability across specialized healthcare settings further strengthen the segment’s dominant position in the amniotic membrane market.
The dehydrated segment is expected to grow at a CAGR of 10.2% during the forecast period, driven by increasing demand for convenient storage and transportation, longer shelf stability, and growing adoption in wound healing and regenerative medicine applications. the segment also benefits from easier handling and broader accessibility across healthcare facilities.
Request Customizationto receive a tailored report.
The surgical wounds segment accounted for a 44.6% share in 2025 and is expected to grow at a CAGR of 9.6% during the forecast period 2026-2034, driven by the increasing use of amniotic membranes for wound healing, tissue regeneration, and management of complex surgical wounds. the growing demand for advanced biological wound care solutions and increasing adoption of regenerative medicine approaches further strengthen the segment’s dominant position in the amniotic membrane market.
The ophthalmology segment supports applications in corneal repair, ocular surface reconstruction, and treatment of various eye disorders, while the others segment includes additional applications across wound care, tissue regeneration, and specialized medical procedures.
The hospitals segment accounted for a share of 47.8% in 2025 due to the widespread use of amniotic membranes in surgical procedures, wound care, ophthalmology, and regenerative medicine applications. the availability of specialized healthcare professionals, advanced medical infrastructure, and high patient volumes further strengthens the segment’s dominant position in the amniotic membrane market.
The ambulatory surgical centres (ASCs) segment is expected to grow at a CAGR of 10.1% during the forecast period, fueled by the increasing shift toward outpatient surgical procedures, growing adoption of minimally invasive treatments, and rising demand for cost-effective and efficient healthcare services. the specialty clinics segment supports specialized applications in ophthalmology, wound care, and regenerative medicine, while the research and academic institutes segment contributes through clinical research, tissue engineering, and development of advanced amniotic membrane applications.
Speak to an Analystto discuss market opportunities.
The North America amniotic membrane market accounted for the largest regional share of 39.2% in 2025, driven by advanced healthcare infrastructure, increasing adoption of regenerative medicine, and growing demand for amniotic membrane products in wound care and ophthalmology. The U.S. amniotic membrane market is supported by the U.S. Food and Drug Administration’s regulation of human amniotic membrane-derived products under its biologics and human cells, tissues, and cellular or tissue-based products framework. Recent FDA enforcement activity in 2025 identified amniotic membrane-derived products being investigated for applications including wound care and orthopedic uses, highlighting continued development and clinical interest in amniotic membrane-based therapies.
The Canada amniotic membrane market is supported by continued clinical use of amniotic membrane tissue, with Canada’s tissue transplantation system recording 334 amniotic membranes transplanted in 2023, according to the Public Health Agency of Canada’s Cells, Tissues and Organs Surveillance System. Health Canada also recognizes amniotic membrane within its regulatory framework for human tissues used in transplantation, supporting the availability and regulated use of these products in clinical applications.
Unlock Regional Insightsto access country-level data, & regional trends.
The Asia Pacific amniotic membrane market is expected to grow at a CAGR of 11.4%, showcasing the fastest-growing regional market, supported by expanding healthcare infrastructure, rising adoption of regenerative medicine, and increasing demand for advanced wound care and tissue repair solutions. In Japan, the Ministry of Health, Labour and Welfare clinical research registry records a 2026 clinical study using hyper-dry human amniotic membrane (HD-AM) for surgical reconstruction of refractory ocular surface diseases, with the study updated on April 16, 2026, indicating continued clinical development and application of amniotic membrane technologies in ophthalmology.
In China, Shenzhen Longgang Central Hospital selected a supplier for ophthalmic biological amniotic membrane in July 2026 as part of its procurement of 11 ophthalmic medical-consumable categories, indicating continued hospital-level adoption of amniotic membrane products for ophthalmic applications. In South Korea, a 2026 study on spontaneous corneal perforation reported that amniotic membrane transplantation was the primary surgical treatment in 50% of cases at the studied South Korean center, demonstrating continued clinical use of amniotic membrane transplantation for corneal and ocular-surface conditions. In India, the Central Government Health Scheme (CGHS) lists amniotic membrane grafting and symblepharon release with AMG per eye as an ophthalmology procedure, while India’s clinical-establishments framework recognizes amniotic membrane graft for cornea and sclera, supporting its continued application in ophthalmic care.
The Europe amniotic membrane market accounted for a regional share of 26.4% in 2025, supported by established healthcare systems, growing adoption of regenerative therapies, and increasing use of amniotic membrane products in clinical applications. In the U.K. amniotic membrane market, the U.K. government published an updated Organs, Tissues and Cells Common Framework in March 2026, maintaining cooperation between the U.K. government and devolved governments on safety and quality standards for non-reproductive human tissues. The Human Tissue Authority specifically includes amniotic membrane among regulated tissues used for human application, including amnion products used as barriers in wound healing.
In the Germany amniotic membrane market, the Paul-Ehrlich-Institut listed multiple authorized amniotic membrane preparations as of August 2026, including cryopreserved and dried products used for applications such as ocular-surface reconstruction and temporary skin replacement. The list also includes products from German tissue institutions and manufacturers in France and the Netherlands. Meanwhile, the France amniotic membrane market recorded strong growth in placental tissue transplantation activity, with 10,580 amniotic membranes distributed to 9,034 recipients in 2024, supplied through donations from 516 women. The French Biomedicine Agency reported that placental tissue graft activity increased by 119% over four years, while validated amniotic membrane stocks covered 87% of the activity recorded in 2024, indicating expanding clinical utilization and supply capacity.
The Middle East and Africa amniotic membrane market is expected to grow at a CAGR of 8.3%, supported by improving healthcare infrastructure, increasing access to advanced wound care solutions, and growing adoption of regenerative medicine technologies. The UAE amniotic membrane market is expected to benefit from the development of regulated tissue-management infrastructure, with the Dubai Health Authority’s Standards for Tissue Management explicitly providing for the use of donated placenta for amniotic membrane grafts and establishing requirements for donor screening, tissue-bank processing, storage, and sterilization, supporting the safe clinical use and availability of amniotic membrane products in Dubai.
The Africa amniotic membrane market is expected to benefit from efforts to strengthen access to quality-assured human tissues and advanced healthcare products, with WHO and the African Medicines Agency establishing a 2026 framework to harmonize regulatory systems and improve access to quality-assured health products across Africa, while WHO’s draft 2026 Global Strategy on Donation and Transplantation aims to improve the availability and safety of human cells, tissues, and organs.
The amniotic membrane market is moderately fragmented, with biotechnology companies, tissue banks, regenerative medicine companies, medical device manufacturers, wound care specialists, and specialized biologics providers competing across ophthalmology, wound care, orthopedics, and regenerative medicine applications. Established players compete primarily on product quality, tissue processing technologies, clinical efficacy, safety, regulatory compliance, product consistency, preservation capabilities, research and development, distribution networks, and clinical support, with leading players such as MiMedx Group Inc., Organogenesis Holdings Inc., Integra LifeSciences Corp., Stryker Corp., and Celularity Inc. estimated to account for approximately 50% of the global market based on their product portfolios, clinical applications, geographic presence, distribution networks, and competitive positioning.
Emerging and regional players within the amniotic membrane market ecosystem compete through cost-effective products, specialized applications, innovative processing methods, customized solutions, localized supply, flexible manufacturing capabilities, and responsive customer support to address specific clinical requirements and strengthen their market presence. These players also focus on developing application-specific tissue products, improving processing techniques, and expanding partnerships with healthcare providers to broaden their market reach.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Organ Preservation Market Size, Share, Growth, Analysis, Report, 2034
Bacteriophage Market Size, Share, Growth, Analysis, 2034
Epigenetics Market Size, Share, Growth, Analysis, Report, 2034
Biobanking Market Size, Share, Growth, 2034
Cell Therapy Manufacturing Market Size, Share, Growth, 2034
Clinical Oncology Next Generation Sequencing Market Size, 2034
We are featured on:
sales@straitsresearch.com